ReviewJournal of the European Academy of Dermatology and Venereology : JEADV2026
Global consensus on the management of melanin hyperpigmentation disorders.
Review in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Beyond Melanin: A Literature Review of Photoprotection Mechanisms and Gaps in Skin of Color.Cureus · 2026Review
- Natural Source, Chemical Classification and Medicinal Application of the Stilbene-Type Compounds: A Review of Structural Modification Around Stilbene Scaffold.Molecules (Basel, Switzerland) · 2026Review
- The Exposome in Melasma: A Comprehensive Review of Etiology, Mechanisms, and Implications for Management.Clinical, cosmetic and investigational dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Melanin hyperpigmentation disorders (MHD) are among the most prevalent dermatologic concerns globally, affecting individuals across all skin phototypes and geographies. Despite their widespread impact on quality of life-including stigmatization, anxiety and depression-comprehensive, unified and practical clinical guidelines are lacking. This global consensus project convened 10 leading dermatologists and pigmentary disorder experts from Africa, Asia, Europe and the Americas to develop an evidence-based, internationally applicable framework for the management of common MHD, including melasma, post-inflammatory hyperpigmentation, acquired dermal macular hyperpigmentation, periorbital hyperpigmentation, chronic hyperpigmentary photodamage, freckles/ephelides and hyperpigmentation of the folds. Based on a comprehensive literature review and a structured Delphi process, the expert panel formulated consensus statements and tailored treatment algorithms that account for skin type, photobiological behaviour, disease severity and regional access to therapies. Special emphasis was placed on the role of broad-spectrum photoprotection and the challenges of tinted sunscreen availability in diverse populations. Treatment options ranged from topical lightening agents and systemic therapies (e.g. oral tranexamic acid) to procedural interventions (e.g. chemical peels, lasers and IPL) stratified by disease subtype and pigmentation depth. Notably, the consensus highlights that effective MHD management must address not only melanocytes but also the surrounding skin microenvironment, including fibroblasts, mast cells and vascular components. This consensus provides a globally adaptable clinical guide for the diagnosis and management of MHD, emphasizing a personalized approach that bridges scientific rigour with real-world applicability across diverse populations and health systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.